Consistent with these findings, we reveal that the emergence of neuroendocrine traits in a relevant prostate tumor cell line model and PC progression to treatment-resistant stages in metastatic PC patient samples are both associated with the loss of RAI2. This evidence concerns the gene RAI2 and pachyonychia congenita.